Tirzepatide, a GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptors co-agonist, was first approved for diabetes treatment in May 2022 [63] and for weight loss in November 2023 [64]. This evidence concerns the gene GLP1R and diabetes mellitus.